Publications des scientifiques de l'IRD

Cisse B., Sokhna C., Boulanger Denis, Milet J., Ba E.H., Richardson K., Hallett R., Sutherland C., Simondon Kirsten, Simondon François, Alexander N., Gaye O., Targett G., Lines J., Greenwood B., Trape Jean-François. (2006). Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children : a randomised, placebo-controlled, double-blind trial. Lancet, 367 (9511), p. 659-667.

Titre du document
Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children : a randomised, placebo-controlled, double-blind trial
Année de publication
2006
Type de document
Article référencé dans le Web of Science WOS:000235611800030
Auteurs
Cisse B., Sokhna C., Boulanger Denis, Milet J., Ba E.H., Richardson K., Hallett R., Sutherland C., Simondon Kirsten, Simondon François, Alexander N., Gaye O., Targett G., Lines J., Greenwood B., Trape Jean-François
Source
Lancet, 2006, 367 (9511), p. 659-667
Background In the Sahel and sub-Sahelian regions of Africa, malaria transmission is highly seasonal. During a short period of high malaria transmission, mortality and morbidity are high in children under age 5 years. We assessed the efficacy of seasonal intermittent preventive treatment-a lull dose of antimalarial treatment given at defined times without previous testing for malaria infection. Methods We did a randomised, placebo-controlled, double-blind trial of the effect of intermittent preventive treatment on morbidity from malaria in three health-care centres in Niakhar, a rural area of Senegal. 1136 children aged 2-59 months received either one dose of artesunate plus one dose of sulfadoxine-pyrimethamine or two placebos on three occasions during the malaria transmission season. The primary outcome was a first or single episode of clinical malaria detected through active or passive case detection. Primary analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT00132561. Findings During 13 weeks of follow-up, the intervention led to an 86% (95% CI 80-90) reduction in the occurrence of clinical episodes of malaria. With passive case detection, protective efficacy against malaria was 86% (77-92), and when detected actively was 86% (78-91). The incidence of malaria in children on active drugs was 308 episodes per 1000 person-years at risk, whereas in those on placebo it was 2250 episodes per 1000 person-years at risk. 13 children were not included in the intention-to-treat analysis, which was restricted to children who received a first dose of antimalarial or placebo. There was an increase in vomiting in children who received the active drugs, but generally the intervention was well tolerated. Interpretation Intermittent preventive treatment could be highly effective for prevention of malaria in children under 5 years of age living in areas of seasonal malaria infection.
Plan de classement
Santé : généralités [050]
Identifiant IRD
PAR00000764
Contact